Latest News
Indivior Pharmaceuticals, Inc.
- Indivior Pharmaceuticals Inc (INDV) Stock Up 4.4% but GF Value Says Overvalued -- GF Score: 83/100
- Third-quarter results are due at 7 a.m. Oct. 29 from Indivior.
- Why Did Indivior Pharmaceuticals (INDV) Stock Slide And What Is Behind It?
- Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.5% -- GF Value Says Still Overvalued
- Indivior Pharmaceuticals : Shareholders Approve Proposed Merger with Supernus
- Barclays cuts target for Indivior stock to USD 43.00
- Indivior Pharmaceuticals Inc (INDV) Stock Down 3.6% but Still Ov
- Indivior: SUBLOCADE Growth And Improving Profitability Create Upside Potential (INDV)
- Indivior to rename as Supernus after merger; supplemental proxy discloses Cantor valuation ranges
- Form 4 INDIVIOR PHARMACEUTICALS For: 6 October By Investing.com
- Legend's five-year data suggests Carvykti could be a cure; Addex and Indivior split up
- Indivior ends PAM drug collab with Addex ahead of Supernus merger
Headlines from the last 30 days, linking to the original publishers. See all market news →